背景:在肾移植患者中,双膦酸盐可以预防骨质流失,但是对它们对骨骼微结构和几何髋关节参数的影响知之甚少,作为骨稳定性的关键因素。本研究旨在分析唑来膦酸对肾移植患者上述参数的影响。
方法:在这种双盲中,随机试验,33名患者在给予4mg唑来膦酸或安慰剂后随访6个月。脊柱骨密度(BMD)测量,臀部,半径,获得了整个身体,使用该软件评估骨小梁评分(TBS)。通过HSA程序对股骨近端进行几何评估。
结果:干预组18例患者和对照组15例患者完成研究。安慰剂组和干预组之间腰椎和全身BMD变化的平均百分比显着不同(-0.23%vs.4.91%和-2.03%与1.23%)(P<0.05)。唑来膦酸似乎增加骨膜下直径,皮质内直径,与安慰剂相比,狭窄颈部的横截面惯性矩(CSMI);但是,两组TBS比较差异无统计学意义(P>0.05)。
结论:我们得出的结论是,唑来膦酸的单次给药可能会改善腰椎和全身的骨丢失,并维持骨膜下直径。皮质内直径,和CSMI作为肾移植受者六个月后股骨近端狭窄颈部骨强度的参数。
背景:该研究于2019年5月4日在IRCT(ID:IRCT20181202041821N1)中注册。
In renal transplant patients, bisphosphonates may prevent bone loss, but little is known about their effects on bone microarchitecture and geometrical hip parameters, as the key factors of bone stability. This
study aimed to analyze the effect of zoledronic acid on the mentioned parameters in kidney transplant patients.
In this double-blind, randomized
trial, 33 patients were followed for six months after administering either 4mg of zoledronic acid or a placebo. Bone mineral density (BMD) measurement of the spine, hip, radius, and whole body was obtained, and trabecular bone score (TBS) was evaluated using the software. Geometric assessment at the proximal femur was performed by the HSA program.
Eighteen patients in the intervention group and 15 in the control group completed the
study. The mean percentages of the changes in the BMD at the lumbar spine and whole body were significantly different between the placebo and intervention groups (-0.23% vs. 4.91% and -2.03% vs. 1.23%) (P < 0.05). Zoledronic acid appeared to enhance the subperiosteal diameter, endocortical diameter, and cross-sectional moment of inertia (CSMI) at the narrow neck in comparison with placebo (P < 0.05); however, no difference in TBS was observed between both groups (P > 0.05).
We concluded that a single administration of zoledronic acid might ameliorate bone loss at the lumbar spine and the whole body and maintain the subperiosteal diameter, endocortical diameter, and CSMI as parameters of bone strength at the narrow neck of the proximal femur after six months in renal-transplant recipients.
This
study was registered in IRCT (ID: IRCT20181202041821N1) on 04-05-2019.